{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:25:54Z","timestamp":1764174354825},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T00:00:00Z","timestamp":1485129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1208\/s12248-017-0047-y","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T20:46:13Z","timestamp":1485204373000},"page":"765-771","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Heparin Purification Process Removes Spiked Transmissible Spongiform Encephalopathy Agent"],"prefix":"10.1208","volume":"19","author":[{"given":"Cyrus","family":"Bett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Grgac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianna","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Karfunkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Keire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Asher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,23]]},"reference":[{"key":"47_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1039\/b819896a","volume":"26","author":"H Liu","year":"2009","unstructured":"Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep. 2009;26:313\u201321.","journal-title":"Nat Prod Rep"},{"key":"47_CR2","first-page":"1911","volume":"30","author":"I DeVeau","year":"2004","unstructured":"DeVeau I, Dabbah R, Sutton S, Analytical Microbiology Expert Committee. The USP perspective to minimize the potential risk of TSE infectivity in bovine-derived articles used in the manufacture of medical products. Pharmacopeial Forum. 2004;30:1911\u201321.","journal-title":"Pharmacopeial Forum"},{"key":"47_CR3","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Biological Hazards (BIOHAZ), European Food Safety Authority. Scientific opinion on BSE risk in bovine intestines. EFSA Journal 2009;7(9):1317, 1\u201319.","DOI":"10.2903\/j.efsa.2009.1317"},{"key":"47_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3201\/eid0701.010102","volume":"7","author":"P Brown","year":"2001","unstructured":"Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis. 2001;7:6\u201316.","journal-title":"Emerg Infect Dis"},{"key":"47_CR5","unstructured":"Center for Disease Control and Prevention. http:\/\/www.cdc.gov\/prions\/bse\/about.html . Accessed 10 Jan 2017."},{"key":"47_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bmb\/66.1.185","volume":"66","author":"PG Smith","year":"2003","unstructured":"Smith PG, Bradley R. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull. 2003;66:185\u201398.","journal-title":"Br Med Bull"},{"issue":"6650","key":"47_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/39057","volume":"389","author":"ME Bruce","year":"1997","unstructured":"Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, et al. Transmissions to mice indicate that \u2018new variant\u2019 CJD is caused by the BSE agent. Nature. 1997;389(6650):498\u2013501.","journal-title":"Nature"},{"issue":"6650","key":"47_CR8","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/38925","volume":"389","author":"AF Hill","year":"1997","unstructured":"Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, et al. The same prion strain causes vCJD and BSE. Nature. 1997;389(6650):448\u201350.","journal-title":"Nature"},{"key":"47_CR9","unstructured":"EuroCJD. European Creutzfeldt-Jakob Disease Survailance Network. EUROCJD Survailance data. http:\/\/www.eurocjd.ed.ac.uk\/surveillance%20data%201.html . Accessed 10 Jan 2017."},{"key":"47_CR10","unstructured":"World Organization for Animal Health (OIE). http:\/\/www.oie.int\/animal-health-in-the-world\/bse-portal\/ . Accessed 10 Jan 2017."},{"key":"47_CR11","unstructured":"USDA. http:\/\/www.fsis.usda.gov\/wps\/portal\/fsis\/topics\/regulatory-compliance\/specified-risk-material\/specified-risk-materials . Accessed 10 Jan 2017."},{"key":"47_CR12","unstructured":"Food and Drug Administration. http:\/\/www.fda.gov\/animalveterinary\/guidancecomplianceenforcement\/complianceenforcement\/bovinespongiformencephalopathy\/default.htm . Accessed 10 Jan 2017."},{"key":"47_CR13","unstructured":"Regulation (EC) no. 999\/2001 of the European Parliament and of the Council, 22 May 2001. http:\/\/eur-lex.europa.eu\/legal-content\/en\/TXT\/PDF\/?uri=CELEX:02001R0999-20130701&from=en . Accessed 10 Jan 2017."},{"key":"47_CR14","unstructured":"Canadian Food Inspection Agency. http:\/\/www.inspection.gc.ca\/animals\/terrestrial-animals\/diseases\/reportable\/bse\/srm\/eng\/1299870250278\/1334278201780 . Accessed 10 Jan 2017."},{"key":"47_CR15","unstructured":"Food and Drug Administration. Response to heparin contamination helped protect public health: controls that were needed for working with external entities were recently added. October 2010. GAO-11-95. http:\/\/www.gao.gov\/assets\/320\/311879.pdf . Accessed 10 Jan 2017."},{"key":"47_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nbt1407","volume":"26","author":"M Guerrini","year":"2008","unstructured":"Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008;26:669\u201375.","journal-title":"Nat Biotechnol"},{"key":"47_CR17","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa0803200","volume":"358","author":"T Kishimoto","year":"2008","unstructured":"Kishimoto T, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358:2457\u201367.","journal-title":"N Engl J Med"},{"key":"47_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/pds.1991","volume":"19","author":"AW McMahon","year":"2010","unstructured":"McMahon AW, Pratt RG, Hammad TA, Kozlowski S, Zhou E, Lu S, et al. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. Pharmacoepidemiol Drug Saf. 2010;19:921\u20133.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"47_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nbt.3606","volume":"34","author":"AY Szajek","year":"2016","unstructured":"Szajek AY, Chess E, Johansen K, Gratzl G, Gray E, Keire D, et al. The US regulatory and pharmacopeia response to the global heparin crisis. Nat Biotechnol. 2016;34(6):625\u201330.","journal-title":"Nat Biotechnol"},{"key":"47_CR20","unstructured":"Keire D, Mulloy B, Chase C, Al-Hakim A, Cairatti D, Gray E, Hogwood J, Morris T, Mour\u00e3o PAS, da Luz Carvalho Soares M, Szajek A. Diversifying the global heparin supply chain: reintroduction of bovine heparin in the United States? Pharm Technol. 2015; 39(11):2\u20138."},{"key":"47_CR21","unstructured":"Food and Drug Administration. 2015 Questions and answers about changes to the USP heparin monograph. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm185913.htm . Accessed 10 Jan 2017."},{"issue":"3","key":"47_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4161\/pri.5.3.16893","volume":"5","author":"R Atarashi","year":"2011","unstructured":"Atarashi R, Sano K, Satoh K, Nishida N. Real-time quaking-induced conversion: a highly sensitive assay for prion detection. Prion. 2011;5(3):150\u20133.","journal-title":"Prion"},{"key":"47_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/128_2011_184","volume":"305","author":"CD Orr\u00fa","year":"2011","unstructured":"Orr\u00fa CD, Caughey B. Prion seeded conversion and amplification assays. Top Curr Chem. 2011;305:121\u201333.","journal-title":"Top Curr Chem"},{"issue":"12","key":"47_CR24","doi-asserted-by":"publisher","first-page":"e1001217","DOI":"10.1371\/journal.ppat.1001217","volume":"6","author":"JM Wilham","year":"2010","unstructured":"Wilham JM, Orr\u00fa CD, Bessen RA, Atarashi R, Sano K, Race B, et al. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog. 2010;6(12):e1001217.","journal-title":"PLoS Pathog"},{"key":"47_CR25","first-page":"183","volume-title":"Techniques in experimental virology","author":"RM Dougherty","year":"1964","unstructured":"Dougherty RM. Animal virus titration techniques. In: Harris RJC, editor. Techniques in experimental virology. New York: Academic; 1964. p. 183\u20136."},{"issue":"9","key":"47_CR26","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1139\/v89-221","volume":"67","author":"M Jaseja","year":"1989","unstructured":"Jaseja M, Rej RN, Sauriol F, Perlin AS. Novel regio- and stereoselective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence. Can J Chem. 1989;67(9):1449\u201356.","journal-title":"Can J Chem"},{"key":"47_CR27","unstructured":"WHO Model List of Essential Medicines 18th list. Final Amendment October 2013 http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/18th_EML.pdf ."},{"key":"47_CR28","unstructured":"Horner AA, Ontario D, Edwards FR. Purification of heparin.\u00a0Patent\u00a0US3179566A. 1965."},{"key":"47_CR29","unstructured":"Coleman LL, Shane RT, Bayard SL. Process for preparing heparin.\u00a0Patent US2954321A. 1960."},{"issue":"1","key":"47_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0008-6215(95)00166-Q","volume":"276","author":"CC Griffin","year":"1995","unstructured":"Griffin CC, Linhardt RJ, Van Gorp CL, Toida T, Hileman RE, Schubert RL, et al. Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin. Carbohydr Res. 1995;276(1):183\u201397.","journal-title":"Carbohydr Res"},{"issue":"9","key":"47_CR31","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1111\/trf.12050","volume":"53","author":"K Cai","year":"2013","unstructured":"Cai K, Gr\u00f6ner A, Dichtelm\u00fcller HO, Fabbrizzi F, Flechsig E, Gajardo R, et al. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. Transfusion. 2013;53(9):1894\u2013905.","journal-title":"Transfusion"},{"issue":"5","key":"47_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s001340051211","volume":"26","author":"S Peano","year":"2000","unstructured":"Peano S, Reiner G, Carbonatto M, Bodenbender L, Boland P, Abel K-J. Determination of the clearance factor for transmissible spongiform encephalopathy agents during the manufacturing process of polygeline. Intensive Care Med. 2000;26(5):608\u201312.","journal-title":"Intensive Care Med"},{"issue":"Pt 12","key":"47_CR33","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1099\/0022-1317-83-12-3199","volume":"83","author":"DM Taylor","year":"2002","unstructured":"Taylor DM, Fernie K, Steele PJ, McConnell I, Somerville RA. Thermostability of mouse-passaged BSE and scrapie is independent of host PrP genotype: implications for the nature of the causal agents. J Gen Virol. 2002;83(Pt 12):3199\u2013204.","journal-title":"J Gen Virol"},{"issue":"Pt 4","key":"47_CR34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/BA20060249","volume":"47","author":"K Fernie","year":"2007","unstructured":"Fernie K, Steele PJ, Taylor DM, Somerville RA. Comparative studies on the thermostability of five strains of transmissible-spongiform-encephalopathy agent. Biotechnol Appl Biochem. 2007;47(Pt 4):175\u201383.","journal-title":"Biotechnol Appl Biochem"},{"issue":"3","key":"47_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1006\/biol.2002.0327","volume":"30","author":"M Vey","year":"2002","unstructured":"Vey M, Baron H, Weimer T, Gr\u00f6ner A. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals. 2002;30(3):187\u201396.","journal-title":"Biologicals"},{"issue":"Suppl 3","key":"47_CR36","first-page":"5","volume":"25","author":"RJ Linhardt","year":"1999","unstructured":"Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:5\u201316.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"47_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1423-0410.2003.00312.x","volume":"85","author":"RW Holten Van","year":"2003","unstructured":"Van Holten RW, Autenrieth SM. Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang. 2003;85(1):20\u20134.","journal-title":"Vox Sang"},{"issue":"4","key":"47_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.biologicals.2008.01.004","volume":"36","author":"M Stucki","year":"2008","unstructured":"Stucki M, Boschetti N, Sch\u00e4fer W, Hostettler T, K\u00e4sermann F, Nowak T, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals. 2008;36(4):239\u201347.","journal-title":"Biologicals"},{"issue":"5","key":"47_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/infdis\/145.2.683","volume":"145","author":"P Brown","year":"1982","unstructured":"Brown P, Rohwer RG, Green EM, Gajdusek DC. Effect of chemicals, heat, and histopathologic processing on high-infectivity hamster-adapted scrapie virus. J Infect Dis. 1982;145(5):683\u20137.","journal-title":"J Infect Dis"},{"key":"47_CR40","unstructured":"WHO tables on tissue infectivity distribution in transmissible spongiform encephalopathies. World Health Organization, 2010 (WHO\/EMP\/QSM\/2010.1). http:\/\/www.who.int\/bloodproducts\/tablestissueinfectivity.pdf?ua=1 . Accessed 17 Jan 2017."},{"key":"47_CR41","unstructured":"Food and Drug Administration. Use of materials derived from cattle in human food and cosmetics. https:\/\/www.gpo.gov\/fdsys\/pkg\/FR-2016-03-18\/pdf\/2016-06123.pdf . Accessed 10 Jan 2017."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-017-0047-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-017-0047-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-017-0047-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:43:21Z","timestamp":1719017001000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-017-0047-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,23]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["47"],"URL":"https:\/\/doi.org\/10.1208\/s12248-017-0047-y","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,23]]}}}